N-(PHENYL)-5-(HETEROARYL)-1H-PYRAZOL-3-AMINE DERIVATIVES AS TANK HIBITORS FOR USE IN CANCER TREATMENT

DE602019084942T2Active Publication Date: 2026-05-13IND ACADEMIC COOP FOUND YONSEI UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
DE602019084942
Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-02-07
Filing Date
2019-01-31
Publication Date
2026-05-13
Estimated Expiration
2039-01-31

AI Technical Summary

Technical Problem

Current TNIK inhibitors are not effective in treating a wide range of cancers and inflammatory diseases, and there is a need for compounds that can synergize with other anticancer drugs to enhance treatment efficacy.

Method used

Development of N-(phenyl)-5-(heteroaryl)-1H-pyrazol-3-amine derivatives that inhibit TNIK activity, which are used in pharmaceutical compositions, either alone or in combination with irinotecan, to treat cancers such as colorectal, breast, brain, gastric, liver, ovarian, lung, and leukemia, targeting cancer stem cells to prevent metastasis and recurrence.

Benefits of technology

The compounds effectively inhibit TNIK activity, showing synergistic effects with irinotecan to treat various cancers and prevent metastasis, while minimizing side effects on normal cells.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.